vaccine

(redirected from DTaP vaccine)
Also found in: Dictionary, Thesaurus, Medical.
Related to DTaP vaccine: Hib vaccine

vaccine:

see vaccinationvaccination,
means of producing immunity against pathogens, such as viruses and bacteria, by the introduction of live, killed, or altered antigens that stimulate the body to produce antibodies against more dangerous forms.
..... Click the link for more information.
.

Vaccine

 

a preparation obtained from microorganisms (bacteria, rickettsias, viruses) or products of their activity and used for active immunization of human beings and animals for prophylactic and therapeutic purposes. Vaccine was first used in 1796 by the English physician E. Jenner, who inoculated persons with cowpox, or vaccinia (hence the name “vaccine”) to protect them against smallpox.

Live, killed, and chemical vaccines and toxoids are distinguished.

Live vaccines are made from specially attenuated cultures of microorganisms deprived of their capacity to cause disease but remaining capable of reproducing in the body and causing immunity. The first to create live vaccines against anthrax (1881) and rabies (1885) was the French microbiologist L. Pasteur. The live tuberculosis vaccine (BCG) proposed in 1926 by the French scientists A. Calmette and C. Guérin won universal recognition; it greatly reduced the tuberculosis rate. Many live vaccines were created by Soviet scientists: for example, typhus vaccine (P. F. Zdrodovskii, 1957-59), influenza vaccine (A. A. Smorodintsev, V. D. Solov’ev, and V. M. Zhdanov, 1960), brucellosis vaccine (P. A. Vershilova, 1947-51), and smallpox vaccine (M. A. Morozov, 1941-60). Vaccines are the only effective inoculative preparations for certain diseases (rabies, smallpox, plague, tularemia). Live vaccines generally produce long-lasting immunity.

Killed vaccines are made from microorganisms killed by physical methods (heating) or chemical methods (phenol, formaldehyde, acetone). Killed vaccines are used to prevent only those diseases for which live vaccines are not available (typhoid, paratyphoid B, whooping cough, cholera, tick-borne encephalitis). They provide less protection than live vaccines. Hence immunity develops only after a course of immunization (vaccination) consisting of several inoculations.

Chemical vaccines are substances isolated from bacterial cells by various chemical methods and containing the main elements that cause immunity. Chemical vaccines against intestinal infections were first employed in 1941 as part of the NIISI polyvalent vaccine proposed by the Soviet scientists N. I. Aleksandrov and N. E. Gefen. Chemical vaccines are used to provide protection against paratyphoid B, typhoid, and rickettsial diseases.

The development of immunity following the injection of toxoids results from the appearance in the blood of antibodies that neutralize the effect of a particular toxin. Toxoids were obtained for the first time during the years 1923-26 by the French scientist G. Ramon. Toxoids are used to prevent diphtheria, tetanus, botulism, gas gangrene, and staphylococcal infections.

Vaccines can be made from the causative agent of a single infection, so-called monovalent vaccines, or from a combination of two or more causative agents, polyvalent vaccines. The latter produce immunity to several infectious diseases.

There are various methods of administering vaccines. In the case of live vaccines, they are related to a certain extent to the routes by which the causative agents enter the body. Thus, poliomyelitis vaccine is administered orally; influenza vaccine intranasally; smallpox, anthrax, and tularemia vaccines epidermally; brucellosis vaccine intradermally; typhus vaccine subcutaneously. Killed vaccines and toxoids are injected subcutaneously or intramuscularly.

Live vaccine is used to treat rabies (vaccine therapy), the only method of protecting man from this fatal disease. Autovaccines are used to treat several chronic inflammatory diseases caused by staphylococci and streptococci.

In the USSR, vaccines are produced by scientific production institutions. The quality of the preparations is controlled by the L. A. Tarasevich State Control Institute for Biomedical Preparations in Moscow.

A. KH. KANCHURIN

Vaccines in veterinary medicine. The principles used in preparing and classifying vaccines for the treatment of animal diseases are the same as those for human diseases. The most widely used live vaccines in veterinary practice include anthrax vaccines—STI and GNKI; swine erysipelas vaccine —from the Konev strain and VR2; brucellosis vaccine— from strain 19; and vaccines against cholera, smallpox, and Newcastle disease. Killed vaccines are used to prevent and treat more than 20 infectious diseases of animals.

REFERENCES

Ramon, G. Sorok let issledovatel’skoi raboty. Moscow, 1962. (Translated from French.)
Vygodchikov, G. V. “Nauchnye osnovy vaktsinno-syvorotochnogo dela.” In Mnogotomnoe rukovodstvo po mikrobiologii, klinike i epidemiologii infektsionnykh boleznei, vol. 3. Moscow, 1964. Pages 485-506.
Kravchenko, A. T., R. A. Saltykov, and F. F. Rezepov. Prakticheskoe rukovodstvo po primeneniiu biologic he skikh preparatov. Moscow, 1968.

A. KH. KANCHURIN
and S. G. KOLESOV

vaccine

[vak′sēn]
(immunology)
A suspension of killed or attenuated bacteria or viruses or fractions thereof, injected to produce active immunity.

vaccine

Med
1. a suspension of dead, attenuated, or otherwise modified microorganisms (viruses, bacteria, or rickettsiae) for inoculation to produce immunity to a disease by stimulating the production of antibodies
2. (originally) a preparation of the virus of cowpox taken from infected cows and inoculated in humans to produce immunity to smallpox
3. of or relating to vaccination or vaccinia
4. Computing a piece of software designed to detect and remove computer viruses from a system
References in periodicals archive ?
She was concerned, however, that infants born to vaccinated mothers mounted only a blunted immune response to their primary DTaP vaccine series, and wondered if responses would be blunted to other vaccines.
Possible ways to create a better DTaP vaccine might involve incorporating a detoxified lipopolysaccharide or adding additional adjuvants to increase the innate immune response to the pertussis antigen.
Major Finding: The risk of pertussis rose 42% per year each year following completion of the DTaP vaccine series, suggesting that the protection it confers drops from approximately 95% to approximately 71% after 5 years.
Since there is no established serologic correlate of protection for pertussis, the antibody responses to each of the three pertussis antigens (PT, FHA, and PRN) of the subjects in this study were compared with those seen in infants following receipt of GlaxoSmithKline's DTaP vaccine (Infanrix).
The investigators examined the durability of the protection provided by the DTaP vaccine by using a case-control study design to compare pertussis incidence between fully vaccinated and unvaccinated children aged 4-10 years who were living in California during the 2010 pertussis epidemic there.
Children receiving the fifth dose of the DTaP vaccine are significantly less likely to experience a local injection site reaction if they receive the injection in the thigh rather than the arm.
Each dose of DTaP-IPV/Hib contains the same diphtheria and tetanus toxoids and pertussis antigens (inactivated pertussis toxin [PT], filamentous hemagglutinin [FHA], pertactin, and fimbriae types 2 and 3) as the FDA-licensed DTaP vaccine Daptacel (Sanofi Pasteur, Toronto, Canada) but contains an increased amount of inactivated PT and FHA (2).
In the interim, neither DT (used in children up to age 7) nor DTaP vaccine should be used as a substitute for Td in people aged 7 or older.
SAN FRANCISCO -- The pertussis component of the DTaP vaccine may not be as immunogenic or long lasting as once thought, said Dr.
McColloster noted that the incidence of pertussis fell in the 10 years after introduction of the DTP (diphtheria, tetanus, pertussis) vaccine, but it actually rose in the 9 years after subsequent introduction of the DTaP vaccine.
During the DTaP vaccine shortage beginning in 2000 (5), ACIP recommended that health-care providers vaccinate infants with the initial 3 DTaP doses, if they did not have insufficient supply of DtaP to vaccinate all children in their practice.
* Thigh swelling and the DTaP vaccine. This one is fairly well established.